Gettman M T, Bergstralh E J, Blute M, Zincke H, Bostwick D G
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.
Urology. 1998 Jan;51(1):79-85. doi: 10.1016/s0090-4295(97)00464-0.
Some patients with palpable intermediate- and high-grade, margin-free, organ-confined prostate cancer experience recurrence following prostatectomy. We studied the ability of microvessel density and other factors to predict recurrence in such patients with pathologic Stage T2 cancer.
Between 1987 and 1991, 307 patients underwent radical prostatectomy for Gleason score 6 to 9, margin-free, organ-confined prostate cancer at Mayo Clinic, Rochester, Minnesota. Specimens from 147 patients with sufficient cancer tissue for immunohistochemical staining with Factor VIII-related antigen were studied by computer-assisted digital image analysis for optimized microvessel density (OMVD). The correlation of deoxyribonucleic acid (DNA) ploidy, Gleason score, OMVD, unilateral disease, bilateral disease, and preoperative prostate-specific antigen (PSA) to cancer recurrence was assessed using the Cox model. Biochemical recurrence was defined as postoperative increase in PSA of greater than 0.2 ng/mL, and clinical recurrence was defined as positive biopsy or metastasis on bone scan.
Mean follow-up for all patients was 6.1 years, with 12 deaths (1 due to prostate cancer) and 58 cases of clinical and/or biochemical recurrence. OMVD was not significantly associated with DNA ploidy, Gleason grade, unilateral disease, bilateral disease, or preoperative PSA. Preoperative PSA was the strongest predictor of clinical and/or biochemical recurrence in both univariate and multivariate analysis. OMVD was not a significant univariate or multivariate predictor of clinical and/or biochemical recurrence. The estimated relative risk of clinical and biochemical recurrence associated with a change in OMVD from the 25th percentile (OMVD 45) to the 75th percentile (OMVD 84) was 1.08 (95% confidence interval 0.79 to 1.47).
Preoperative PSA was the strongest predictor of clinical and/or biochemical recurrence of prostate cancer in this group of patients. Optimized microvessel density did not predict outcome in a select cohort of patients with palpable intermediate- and high-grade, margin-free, organ-confined prostate cancer (TNM stage T2N0M0).
一些可触及的中高级别、切缘阴性、器官局限性前列腺癌患者在前列腺切除术后会出现复发。我们研究了微血管密度及其他因素预测此类病理分期为T2期癌症患者复发的能力。
1987年至1991年间,307例患者在明尼苏达州罗切斯特市的梅奥诊所接受了根治性前列腺切除术,这些患者的 Gleason评分6至9分,切缘阴性,器官局限性前列腺癌。对147例有足够癌组织用于因子VIII相关抗原免疫组化染色的患者标本,采用计算机辅助数字图像分析来测定优化微血管密度(OMVD)。使用Cox模型评估脱氧核糖核酸(DNA)倍体、Gleason评分、OMVD、单侧疾病、双侧疾病和术前前列腺特异性抗原(PSA)与癌症复发的相关性。生化复发定义为术后PSA升高超过0.2 ng/mL,临床复发定义为活检阳性或骨扫描有转移。
所有患者的平均随访时间为6.1年,有12例死亡(1例死于前列腺癌)以及58例临床和/或生化复发。OMVD与DNA倍体、Gleason分级、单侧疾病、双侧疾病或术前PSA均无显著相关性。在单因素和多因素分析中,术前PSA都是临床和/或生化复发的最强预测因子。OMVD不是临床和/或生化复发的显著单因素或多因素预测因子。OMVD从第25百分位数(OMVD 45)变化到第75百分位数(OMVD 84)时,临床和生化复发的估计相对风险为1.08(95%置信区间0.79至1.47)。
术前PSA是该组患者前列腺癌临床和/或生化复发的最强预测因子。在一组可触及的中高级别、切缘阴性、器官局限性前列腺癌(TNM分期T2N0M0)患者中,优化微血管密度并不能预测预后。